A new model for drug discovery - Meeting our societal obligation

Drug Discovery Today

Volumn 8, Issue 6, 2003, Pages 245-248

  Stein, Ross L ^a  

^a The Harvard Center for Neurodegeneration & Repair   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVATOR; ENZYME INHIBITOR; RECEPTOR BLOCKING AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; BIOINFORMATICS; CELL ASSAY; DEGENERATIVE DISEASE; DRUG INDUSTRY; DRUG TARGETING; HUMAN; HUNTINGTON CHOREA; LABORATORY; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICAL STAFF; MULTIPLE SCLEROSIS; PROTEIN AGGREGATION; PROTEIN POLYMERIZATION; REVIEW; SOCIOECONOMICS;

EID: 0037443798     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02594-1     Document Type: Note

References (6)

1. Kell D.B. Screen idols: faster, smaller, cheaper, and smarter. Trends Biotechnol. 18:2000;186-187.
2. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26.
3. Liu Y., et al. The UCH-l1 gene encodes two opposing enzymatic activities that affect a-synculein degradation and Parkinson's disease susceptibility. Cell. 111:2002;209-218.
4. Kurochkin I.V. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci. 26:2001;421-425.
5. Madsen L.S., et al. A humanized model for multiple schlerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23:1999;343-347.
6. Huang C.C., et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24:1998;217-233.